Catarina Ihre proposed as a new member of Brighter's Board of Directors.

08:30 / 18 April 2018 Brighter Press release

At Brighter's upcoming annual general shareholders meeting, the Company's Nomination Committee will propose changes to the Board of Directors, with Catarina Ihre as a new member on the board. Catarina Ihre has worked as an analyst at Deutsche Bank and Nordea and in Investor Relations at Lundin Mining, SSAB and Electrolux. At Electrolux she held the position of VP Investor Relations.

 "I look forward to working with Brighter, a visionary company with high ambitions in a very large market. Healthcare must be cheaper, more digital and help patients get higher quality of life. This is what Brighter's first solution Aciste® means for diabetes, one of the world's largest diseases, says Catarina Ihre.

Catarina Ihre holds a degree in Economics from Uppsala University. She has worked for 15 years as an analyst and for 11 years as IR manager in three of the 30 companies whose stock is traded most on Nasdaq Stockholm.
"I am very pleased that Catarina wants to help Brighter to navigate in what I expect to be a very offensive and expansive period. Her deep global experience from both the investor and the corporate side of investor relations will strengthen the board's work on many levels, says Brighter's founder and CEO Truls Sjöstedt.

For more information, please contact:

Truls Sjöstedt, CEO 
Telefon: +46 709 73 46 00      

Henrik Norström, COO   
Telefon: +46 733 40 30 45      

About Brighter
Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of healthcare's biggest challenges: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing, and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop™ - is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their close associates, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole.

About Actiste
Brighter's solution Actiste® handles most of the self-monitoring and treatment of insulin-treated diabetes in a single easy-to-use device. Measurement of glucose levels, insulin injections, automatic logging, and timing of all activities are performed from a single unit. Actiste is connected via an autonomous and secure mobile connection, and information can be automatically shared with selected recipients through The Benefit Loop®, Brighter's open cloud-based service where data is collected, processed and analyzed with patient consent.

Validated user-generated data, such as test results, can be automatically transferred electronically to many different constituents. The patient selects when and how data is shared and who will have access to it. Through The Benefit Loop, different services can motivate patients with chronic illnesses to change their behavior, which can save lives, reduce relatives' concerns, and release enormous healthcare resources.

 ( Company's shares are listed on NASDAQOMX First North/BRIG ( Brighter's Certified Adviser on Nasdaq OMX First North is Remium Nordic Holding AB +46 (0)8 - 454 32 50,,

Show as PDF

Show original from Cision


This information was distributed by Cision